Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial-Reference-Cited by-同舟云学术

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Published:2018-11-11 Issue:3 Volume:21 Page:499-508
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bain Stephen C.¹^ORCID,Mosenzon Ofri²,Arechavaleta Rosario³,Bogdański Pawel⁴,Comlekci Abdurrahman⁵,Consoli Agostino⁶,Deerochanawong Chaicharn⁷,Dungan Kathleen⁸^ORCID,Faingold Maria C.⁹,Farkouh Michael E.¹⁰,Franco Denise R.¹¹,Gram Jeppe¹²,Guja Cristian¹³^ORCID,Joshi Pankaj¹⁴,Malek Rachid¹⁵,Merino-Torres Juan F.¹⁶,Nauck Michael A.¹⁷^ORCID,Pedersen Sue D.¹⁸,Sheu Wayne H. -H.¹⁹²⁰²¹,Silver Robert J.²²,Tack Cees J.²³,Tandon Nikhil²⁴,Jeppesen Ole K.²⁵,Strange Mette²⁵,Thomsen Mette²⁵,Husain Mansoor¹⁰²⁶

Affiliation:

1. Diabetes Research Unit Cymru; Swansea University Medical School; Swansea UK

2. Diabetes Unit, Division of Internal Medicine; Hadassah Hebrew University Hospital; Jerusalem Israel

3. Department of Endocrinology, Universidad Autonoma de Guadalajara; Jalisco Mexico

4. Department of Education and Obesity Treatment and Metabolic Disorders; Poznan University of Medical Sciences; Poznan Poland

5. Department of Endocrinology; Dokuz Eylul University Faculty of Medicine, Balcova; Izmir Turkey

6. Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met); "G. d'Annunzio" University of Chieti-Pescara; Chieti Italy

7. Diabetes and Endocrinology Unit, Rajavithi Hospital; Rangsit Medical School; Bangkok Thailand

8. Division of Endocrinology, Diabetes and Metabolism; Ohio State University; Columbus Ohio

9. Department of Endocrinology and Metabolism; Dr Cesar Milstein Hospital; Buenos Aires Argentina

10. Peter Munk Cardiac Centre, University Health Network, Department of Medicine and the Heart and Stroke Richard Lewar Centre; University of Toronto; Toronto Ontario Canada

11. CPCLIN Clinical Research Center; São Paulo Brazil

12. Department of Endocrinology; Hospital of Southwest Denmark; Esbjerg Denmark

13. Department of Diabetes, Nutrition and Metabolic Diseases; University of Medicine and Pharmacy 'Carol Davila'; Bucharest Romania

14. Diabetes Care and Clinical Trials Centre; Pretoria South Africa

15. Department of Internal Medicine; CHU Sétif; Sétif Algeria

16. Department of Endocrinology and Nutrition; University Hospital La Fe; Valencia Spain

17. Diabetes Center Bochum-Hattingen, Medical Department I; St Josef-Hospital, Ruhr-University Bochum; Bochum Germany

18. C-ENDO Diabetes and Endocrinology Clinic; Calgary Alberta, Canada

19. Division of Endocrinology and Metabolism, Department of Internal Medicine; Taichung Veterans General Hospital; Taichung Taiwan

20. School of Medicine; National Yang-Ming University; Taipei Taiwan

21. School of Medicine; National Defense Medical Centre; Taipei Taiwan

22. Southern New Hampshire Diabetes and Endocrinology; Nashua New Hampshire

23. Department of Internal Medicine; Radboud University Medical Center; Nijmegen The Netherlands

24. Department of Endocrinology and Metabolism; All India Institute of Medical Sciences; New Delhi India

25. Novo Nordisk A/S; Bagsvaerd Denmark

26. Toronto General Hospital Research Institute, and the Ted Rogers Centre for Heart Research; Toronto Canada

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13553/fullpdf

Reference40 articles.

1. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018;American Diabetes Association;Diabetes Care,2018

2. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetologia,2015

3. GLP-1 agonists and blood pressure: a review of the evidence;Goud;Current Hypertens Rep,2016

4. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016

5. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study;Fu;Diabetes Technol Ther,2014

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6;Nephrology Dialysis Transplantation;2024-07-02

3. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease;Frontiers in Pharmacology;2024-04-24

4. From a glycocentric approach in the patient with type 2 diabetes mellitus to a multi-organ prevention treatment and a decrease in the neuro-nephro-cardiovascular outcomes.;Type 2 Diabetes - From Diagnosis to Effective Management [Working Title];2023-10-03

5. Insulin Resistance and Insulin Handling in Chronic Kidney Disease;Comprehensive Physiology;2023-09-28